Inozyme Pharma, Inc.
NASDAQ:INZY
5.15 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 34.588 | 32.915 | 23.316 | 159.896 | 31.605 | 35.966 |
| Short Term Investments
| 154.001 | 94.951 | 88.485 | 119.657 | 15.527 | 7.197 |
| Cash and Short Term Investments
| 188.589 | 127.866 | 111.801 | 159.896 | 47.132 | 43.163 |
| Net Receivables
| 0.385 | 0.115 | 0.062 | 0.155 | 0.104 | 0.031 |
| Inventory
| 0 | -0.115 | -0.062 | -12.354 | 0 | 0 |
| Other Current Assets
| 7.276 | 3.527 | 3.541 | 3.282 | 0.224 | 0.073 |
| Total Current Assets
| 196.25 | 131.393 | 115.342 | 150.979 | 47.46 | 43.267 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 2.592 | 3.638 | 4.436 | 2.648 | 0.298 | 0.242 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0.311 | 0.354 | 0.354 | 12.199 | 0.13 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 1.694 | 3.81 | 3.409 | 3.537 | 0.056 | 0.034 |
| Total Non-Current Assets
| 4.597 | 7.802 | 8.199 | 18.384 | 0.484 | 0.276 |
| Total Assets
| 200.847 | 139.195 | 123.541 | 169.363 | 47.944 | 43.543 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 1.166 | 2.544 | 2.394 | 3.069 | 0.901 | 0.984 |
| Short Term Debt
| 0.91 | 0.816 | 0.731 | -0.279 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 3.81 | 0 | 0.279 | 0 | 0 |
| Other Current Liabilities
| 12.61 | 7.545 | 8.508 | 6.904 | 2.335 | 1.405 |
| Total Current Liabilities
| 14.686 | 14.715 | 11.633 | 9.973 | 3.236 | 2.389 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 44.769 | 5.962 | 2.64 | 1.287 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0.913 | 0.124 | 0 | 0 | 0 | 55.029 |
| Total Non-Current Liabilities
| 45.682 | 6.086 | 2.64 | 1.287 | 77.927 | 55.029 |
| Total Liabilities
| 60.368 | 20.801 | 14.273 | 11.26 | 81.163 | 57.418 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 123.541 | 169.363 | 77.927 | 55.029 |
| Common Stock
| 0.006 | 0.004 | 0.002 | 0.002 | 0.001 | 0.001 |
| Retained Earnings
| -285.93 | -214.761 | -147.7 | -91.076 | -34.652 | -14.928 |
| Accumulated Other Comprehensive Income/Loss
| 0.041 | -0.205 | 0.018 | 0.002 | 0.005 | -0.002 |
| Other Total Stockholders Equity
| 426.362 | 333.557 | 133.407 | 79.808 | -76.5 | -53.975 |
| Total Shareholders Equity
| 140.479 | 118.595 | 109.268 | 158.099 | -33.219 | -13.875 |
| Total Equity
| 140.479 | 118.595 | 109.268 | 158.099 | -33.219 | -13.875 |
| Total Liabilities & Shareholders Equity
| 200.847 | 139.396 | 123.541 | 169.359 | 47.944 | 43.543 |